RS62809B1 - Modulatori ccr2 - Google Patents
Modulatori ccr2Info
- Publication number
- RS62809B1 RS62809B1 RS20220041A RSP20220041A RS62809B1 RS 62809 B1 RS62809 B1 RS 62809B1 RS 20220041 A RS20220041 A RS 20220041A RS P20220041 A RSP20220041 A RS P20220041A RS 62809 B1 RS62809 B1 RS 62809B1
- Authority
- RS
- Serbia
- Prior art keywords
- ccr2 modulators
- ccr2
- modulators
- Prior art date
Links
- 101150083327 CCR2 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Amplifiers (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164957P | 2015-05-21 | 2015-05-21 | |
| PCT/US2016/033210 WO2016187393A1 (en) | 2015-05-21 | 2016-05-19 | Ccr2 modulators |
| EP16797279.3A EP3297438B1 (en) | 2015-05-21 | 2016-05-19 | Ccr2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62809B1 true RS62809B1 (sr) | 2022-02-28 |
Family
ID=57320660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220041A RS62809B1 (sr) | 2015-05-21 | 2016-05-19 | Modulatori ccr2 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9783540B2 (sr) |
| EP (1) | EP3297438B1 (sr) |
| JP (1) | JP6841771B2 (sr) |
| KR (1) | KR102622891B1 (sr) |
| CN (1) | CN108135168B (sr) |
| AR (1) | AR104720A1 (sr) |
| AU (1) | AU2016263579B2 (sr) |
| BR (1) | BR112017024555A2 (sr) |
| CA (1) | CA2985194C (sr) |
| CY (1) | CY1124918T1 (sr) |
| DK (1) | DK3297438T3 (sr) |
| ES (1) | ES2904252T3 (sr) |
| HR (1) | HRP20220028T1 (sr) |
| HU (1) | HUE060376T2 (sr) |
| IL (1) | IL255509B (sr) |
| LT (1) | LT3297438T (sr) |
| MA (1) | MA42133A (sr) |
| MX (1) | MX2017014375A (sr) |
| NZ (1) | NZ737399A (sr) |
| PL (1) | PL3297438T3 (sr) |
| PT (1) | PT3297438T (sr) |
| RS (1) | RS62809B1 (sr) |
| RU (1) | RU2726206C2 (sr) |
| SI (1) | SI3297438T1 (sr) |
| TW (1) | TWI733670B (sr) |
| WO (1) | WO2016187393A1 (sr) |
| ZA (1) | ZA201707966B (sr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9046025B2 (en) | 2013-06-07 | 2015-06-02 | GM Global Technology Operations LLC | Selective catalytic reduction device monitoring system |
| HUE060376T2 (hu) | 2015-05-21 | 2023-02-28 | Chemocentryx Inc | Ccr2 modulátorok |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| SG11201809751XA (en) | 2016-05-26 | 2018-12-28 | Zeno Royalties & Milestones Llc | Egfr inhibitor compounds |
| WO2018237383A1 (en) * | 2017-06-23 | 2018-12-27 | The Trustees Of Columbia University In The City Of New York | METHODS OF PREVENTING AND TREATING DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERATION, INCLUDING ALZHEIMER'S DISEASE |
| CN111712242B (zh) * | 2017-09-25 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| SG11202002975YA (en) * | 2017-10-11 | 2020-04-29 | Chemocentryx Inc | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| WO2019136368A2 (en) * | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| WO2019149089A1 (zh) * | 2018-02-02 | 2019-08-08 | 四川科伦博泰生物医药股份有限公司 | 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途 |
| WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CA3135694A1 (en) | 2019-04-17 | 2020-10-22 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| CN114206338A (zh) | 2019-07-10 | 2022-03-18 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| WO2021018866A1 (en) * | 2019-07-30 | 2021-02-04 | Edvince Ab | Mek inhibitor for treatment of stroke |
| CN112773805B (zh) * | 2019-11-11 | 2024-05-10 | 中国科学院脑科学与智能技术卓越创新中心 | 缺血性脑损伤的新型治疗药物 |
| CN111139294A (zh) * | 2020-01-06 | 2020-05-12 | 中国药科大学 | Fdps在制备治疗非酒精性脂肪性肝炎药物中的应用 |
| AU2021235304A1 (en) * | 2020-03-10 | 2022-10-06 | Redhill Biopharma Ltd. | Treatment of coronavirus infection |
| CN111423454B (zh) * | 2020-04-24 | 2021-06-22 | 苏州大学 | 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1440402A (zh) | 2000-06-30 | 2003-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 作为趋化因子受体活性调节剂的n－脲基杂环烷基－哌啶 |
| ES2271063T3 (es) | 2000-08-17 | 2007-04-16 | MERCK & CO., INC. | Moduladores ciclopentilos de la actividad del receptor de la quimioquina. |
| WO2003004487A1 (en) | 2001-07-02 | 2003-01-16 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| US20060030582A1 (en) | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| JO2479B1 (en) * | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
| AU2003223755B2 (en) | 2002-04-29 | 2008-08-21 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| PT1501507E (pt) * | 2002-04-29 | 2008-08-12 | Merck Sharp & Dohme | Tetrahidropiranil ciclopentil tetrahidropiridopiridinas moduladoras da actividade dos receptores de quimioquinas |
| US7491737B2 (en) | 2002-10-30 | 2009-02-17 | Merck & Co., Inc. | Heterarylpiperidine modulators of chemokine receptor activity |
| AU2004215409B2 (en) | 2003-02-24 | 2008-11-20 | Merck Sharp & Dohme Corp. | Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| WO2004082682A1 (en) | 2003-03-18 | 2004-09-30 | Merck & Co. Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
| RU2301802C2 (ru) | 2003-04-15 | 2007-06-27 | Мерк Энд Ко., Инк. | Бензоксазинил-амидоциклопентил-гетероциклические модуляторы хемокиновых рецепторов |
| WO2004094371A2 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2004110376A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Ccr-2 antagonists for treatment of neuropathic pain |
| AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
| AU2004287416C1 (en) | 2003-10-27 | 2010-09-09 | Merck Sharp & Dohme Corp. | CCR-2 antagonist salt |
| AU2004313486A1 (en) * | 2004-01-02 | 2005-07-28 | Merck & Co., Inc. | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity |
| CN1918145A (zh) * | 2004-02-12 | 2007-02-21 | 默克公司 | 作为趋化因子受体活性调节剂的氨基杂环类化合物 |
| US7307086B2 (en) | 2004-05-11 | 2007-12-11 | Incyte Corporation | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors |
| UY29219A1 (es) | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
| CA2593545A1 (en) | 2005-01-06 | 2006-07-13 | Merck & Co., Inc. | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders |
| CN100364643C (zh) * | 2006-05-11 | 2008-01-30 | 同济大学 | 一种从排气中吸附回收净化有机物的方法和装置 |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
| ES2383568T3 (es) | 2007-07-12 | 2012-06-22 | Chemocentryx, Inc. | Heteroaril piridil y fenil bencenosulfonamidas condensadas como moduladores de CCR2 para el tratamiento de la inflamación |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
| TW201033204A (en) | 2008-12-10 | 2010-09-16 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| AU2010236393B2 (en) | 2009-04-16 | 2014-11-13 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 |
| NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| EP3091012B1 (en) * | 2009-12-17 | 2018-04-11 | Centrexion Therapeutics Corporation | Ccr2 receptor antagonists and uses thereof |
| WO2011100227A1 (en) | 2010-02-09 | 2011-08-18 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
| US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| ES2550312T3 (es) | 2010-06-17 | 2015-11-06 | Janssen Pharmaceutica Nv | Antagonistas ciclohexil-azetidinilo de CCR2 |
| ES2666870T3 (es) * | 2011-03-10 | 2018-05-08 | Daiichi Sankyo Company, Limited | Derivado de dispiropirrolidina |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
| CA2877814A1 (en) | 2012-06-22 | 2013-12-27 | Dingqiu HUANG | Antigen binding proteins that bind ccr2 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| AU2014290069B2 (en) | 2013-07-16 | 2019-01-03 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
| ES2827679T3 (es) | 2013-08-20 | 2021-05-24 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib |
| MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6405457B2 (ja) | 2014-09-11 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐｄ−１／ｐｄ−ｌ１およびｃｄ８０（ｂ７−１）／ｐｄ−ｌ１タンパク質／タンパク質相互作用の大環状阻害剤 |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| HUE060376T2 (hu) | 2015-05-21 | 2023-02-28 | Chemocentryx Inc | Ccr2 modulátorok |
| WO2017165125A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
| WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN111712242B (zh) | 2017-09-25 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| US20190224205A1 (en) | 2018-01-22 | 2019-07-25 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
-
2016
- 2016-05-19 HU HUE16797279A patent/HUE060376T2/hu unknown
- 2016-05-19 DK DK16797279.3T patent/DK3297438T3/da active
- 2016-05-19 BR BR112017024555A patent/BR112017024555A2/pt not_active Application Discontinuation
- 2016-05-19 MA MA042133A patent/MA42133A/fr unknown
- 2016-05-19 HR HRP20220028TT patent/HRP20220028T1/hr unknown
- 2016-05-19 CA CA2985194A patent/CA2985194C/en active Active
- 2016-05-19 RU RU2017144651A patent/RU2726206C2/ru active
- 2016-05-19 AU AU2016263579A patent/AU2016263579B2/en active Active
- 2016-05-19 EP EP16797279.3A patent/EP3297438B1/en active Active
- 2016-05-19 MX MX2017014375A patent/MX2017014375A/es unknown
- 2016-05-19 SI SI201631442T patent/SI3297438T1/sl unknown
- 2016-05-19 WO PCT/US2016/033210 patent/WO2016187393A1/en active Application Filing
- 2016-05-19 KR KR1020177036757A patent/KR102622891B1/ko active IP Right Grant
- 2016-05-19 NZ NZ737399A patent/NZ737399A/en unknown
- 2016-05-19 ES ES16797279T patent/ES2904252T3/es active Active
- 2016-05-19 PT PT167972793T patent/PT3297438T/pt unknown
- 2016-05-19 CN CN201680029546.7A patent/CN108135168B/zh active Active
- 2016-05-19 LT LTEPPCT/US2016/033210T patent/LT3297438T/lt unknown
- 2016-05-19 US US15/158,713 patent/US9783540B2/en active Active
- 2016-05-19 JP JP2017560247A patent/JP6841771B2/ja active Active
- 2016-05-19 PL PL16797279T patent/PL3297438T3/pl unknown
- 2016-05-19 RS RS20220041A patent/RS62809B1/sr unknown
- 2016-05-20 TW TW105115844A patent/TWI733670B/zh active
- 2016-05-20 AR ARP160101482A patent/AR104720A1/es active IP Right Grant
-
2017
- 2017-08-31 US US15/692,811 patent/US10464934B2/en active Active
- 2017-11-07 IL IL255509A patent/IL255509B/en active IP Right Grant
- 2017-11-23 ZA ZA2017/07966A patent/ZA201707966B/en unknown
-
2019
- 2019-09-23 US US16/579,488 patent/US20200121688A1/en not_active Abandoned
-
2021
- 2021-06-24 US US17/357,427 patent/US12054484B2/en active Active
-
2022
- 2022-01-19 CY CY20221100047T patent/CY1124918T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201707966B (en) | Ccr2 modulators | |
| HK1244652A1 (zh) | 可操縱微型內窺鏡 | |
| GB201506824D0 (en) | TrailReach Multitrial | |
| GB201413018D0 (en) | Beyond 1A | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| GB201500806D0 (en) | Aerosol-gnerating aticle | |
| IL266261A (en) | ror-gamma modulators | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| DK3336185T3 (en) | Antistof | |
| DK3272750T3 (en) | Morphinan-derivat | |
| GB201509499D0 (en) | Zkd | |
| GB201503400D0 (en) | Ink | |
| GB201502316D0 (en) | Bitcon technology | |
| GB201502073D0 (en) | HDEG technology | |
| GB201522365D0 (en) | Concept abcd12 | |
| GB201400215D0 (en) | Modulators | |
| GB201520415D0 (en) | Roadplate | |
| GB201518520D0 (en) | Concept ABCD4 | |
| GB201517489D0 (en) | NoFlat | |
| GB201515216D0 (en) | Concept B | |
| GB201513704D0 (en) | Hardwater | |
| GB201511392D0 (en) | Uveclip | |
| GB201502544D0 (en) | Independent means |